FINO2 Compound for Ferroptosis
FINO2 is a ferroptosis-inducing peroxide compound that indirectly inhibits glutathione peroxidase 4 (GPX4) and oxidizes iron.
OT-II LAG-3-/- mouse
These mice can be used for investigating LAG-3 and developing therapeutics that target LAG-3 dimerization, which is implicated in a variety of conditions, such as cancer and autoimmune diseases.
OT-I LAG-3-/- mouse
These mice can be used for investigating LAG-3 and developing therapeutics that target LAG-3 dimerization, which is implicated in a variety of conditions, such as cancer and autoimmune diseases.
RAGE conditional knockout transgenic mice (Columbia)
RAGE conditional knockout transgenic mice are useful for studying the deletion of RAGE which is implicated in energy metabolism and obesity.
AGER Conditional Knockout Transgenic Mice (Columbia)
AGER conditional knockout transgenic mice are useful for studying the deletion of Ager, a gene encoding RAGE, that is implicated in energy metabolism and obesity.
Diaph1 conditional knockout transgenic mice (Columbia)
These conditional knockout transgenic mice are useful for studying Diaphanous-1 (DIAPH1) and its role in tissue ischemia since DIAPH1 regulates actin dynamics, signal transduction, and metabolic functions.
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Brca1 -/-; MycOE
An engineered murine fallopian tube epithelial cell line with rp53 -/-; Brca1 -/-; MycOE mutations models high-grade serous tubo-ovarian carcinoma (HGSC) for studying tumor biology and testing new therapies
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Ccne1OE; MycOE
A novel murine cell line derived from fallopian tubes with specific genetic alterations mimics human CCNE1-driven high-grade serous tubo-ovarian cancer (HGSC), enabling in vivo and in vitro studies to explore tumor-immune interactions and test new therapies.
B6.Cg-Ptprca Cx3cr1tm1Litt/LittJ (Jax No. 008451) Transgenic mice
These CX3CR1-GFP knock-in/knock-out mice express EGFP under control of the endogenous Cx3cr1 locus and also harbor the CD45.1 (Ly5.1 or Ptprca) allele, which is atypical for the C57BL/6 congenic background and may be useful in studies of leukocyte migration and trafficking, as well as for transplantation studies with C57BL/6 (CD45.2: Ptprcb) mice.
GHOST (3) CXCR4+CCR5+ cell line (NIH AIDS Reagent Program Catalog Number: 3942) (HHMI)
This cell line expresses CXCR4 and CCR5 on surface and also contains an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
Mouse IgG1 monoclonal antibodies directed to human ROR gamma (DNA binding domain) produced by clone 4F3-3C8-2B7 (HHMI)
This mAb can be used to study inflammation and immunology related to Retinoid-Related Orphan Receptor(ROR) γ T. The clone has been validated for use in WB, FC & IF.
B6.129P2-Runx1tm1Tani/J transgenic mice (HHMI) (Jax No. 008772)
Exon 4 of these Runx1 (runt related transcription factor 1) targeted mutant mice is flanked by loxP sites. When crossed with a Cre recombinase-expressing strain, this strain is useful in eliminating tissue-specific expression of the gene. When crossed to a CD4-cre mouse strain, progeny have fewer CD4+ T cells than wildtype mice and completely lack NK T cells.
C57BL/6-Tg(Tcra,Tcrb)2Litt/J transgenic mice (HHMI) (Jax. No. 027230)
T cells from these TCR transgenic mice recognize intestinal segmented filamentous bacteria (SFB) and predominantly become TH17 cells in SFB-colonized mice. These mice, derived from clone 7B8, are useful in studies of the relationship between commensal microbiota and organ-specific autoimmunity.
DC-SIGN transgenic mice (HHMI)
These transgenic mice expressing human DC-SIGN show reduced tissue damage and prolonged survival during mycobacterial infection, suggesting a protective role for DC-SIGN in limiting tuberculosis-induced pathology.
B6.FVB-Tg(Rorc-cre)1Litt/J transgenic mice (Jax. No 022791) (HHMI)
These transgenic mice express cre recombinase under the control of the mouse Rorc (RAR-related orphan receptor gamma; also called RORγt) promoter. Expression can be found in double positive thymocytes and their CD4+ and CD8+ single positive progeny as well as all αβ T cells of the spleen and lymphoid tissue inducer cells (LTi) and RORG+ innate lymphoid cells.
C57BL/6-Tg(Cd8a-cre)1ltan/J transgenic mice (Jax No. 008766) (HHMI)
These Cd8a-Cre transgenic mice have Cre recombinase activity observed in peripheral CD8+ T cells (CD8α+CD8β+ αβT cells and CD8α+CD8β- αβT cells, but not in CD4+CD8α-CD8β- αβT cells). The transgenic construct also contains GFP, which co-expresses with Cre, but the GFP expression is very low via flow cytometry. These mice may be useful for deletion of loxP-flanked sequences in CD8a-expressing cells.
Humanized mouse line expressing the human WT or CX3CR1I249/ M280 polymorphic variant (HHMI/USTA)
This mouse model expresses the human version of the receptor CX3CR1 harboring the sequence I249/M280 and can be used to study neuroinflammatory processes related to microglia-neuron communication in neurodegenerative diseases.
C.129P2-Cxcr6tm1Litt/J transgenic mice (HHMI) (Jax No. 005700)
In these Cxcr6 knock-out/reporter mice EGFP expression is restricted to spleen and lymph nodes. They are suitable for use in applications related to studies of hepatitis and various immune responses.
B6.129P2-Cxcr4tm2Yzo/J transgenic mice (HHMI) (Jax No. 008767)
These mice possess loxP sites on either side of exon 2 of the Cxcr4, chemokine (C-X-C motif) receptor 4 gene. When crossed with a cre recombinase-expressing strain, this strain is useful in eliminating tissue-specific expression of the gene.
Plasmid SV-Ψ-MLV-env- (BEI catalog # 3422)
This plasmid, pSV-Ψ-MLV-env-, can produce high-titer murine leukemia virus (MLV) retroviral vectors.
SERPINB2 deficient cell lines for enhanced AdV manufacturing purposes
These cell lines lack SERPINB2 (Serine Protease Inhibitor) which yields increased titers during manufacturing processes. Infectious particle yield is a major bottleneck in the production of adenovirus as gene vectors in oncology and vaccines.
Axsl1 fl/fl:Tet2 fl/fl Conditional Knockout Mice
These conditional knockout mice are useful for studying and characterizing the role of Axsl1 and Tet2 in myeloid malignancies, such as myelodysplastic syndromes (MDSs).
Susd6 fl/fl Conditional Knockout Mice
These conditional knockout mice are useful for studying and characterizing the role of Susd6 in Acute Myeloid Leukemia (AML) and multiple solid tumor cancers.
Clpb fl/fl Conditional Knockout Mice
These conditional knockout mice are useful for studying and characterizing the role of Clpb in mitochondrial dysfunction in diseases such as Acute Myeloid Leukemia (AML).
C57BL/6 (Rosa-rtTA shTet3)
These reversible RNAi transgenic mice can be used to model knockdown and restoration of endogeous Tet3 in hematopoietic cells for TET3 mutant diseases.
C57BL/6 (Rosa-rtTA shTet2)
These reversible RNAi transgenic mice can be used to model knockdown and restoration of endogeous Tet2 in hematopoietic cells for TET2 mutant diseases.
C57BL/6 (Rosa-rtTA shTet1)
These reversible RNAi transgenic mice can be used to model knockdown and restoration of endogeous Tet1 in hematopoietic cells for TET1 mutant diseases.
Conditional AsxL1 Knock-out Mouse Model (Jax No. 025665)
These floxed mutant mice possess loxP sites flanking exons 5 through 10 of the Asxl1 gene and may be useful for generating conditional mutations in applications related to embryonic development, myelodysplastic syndromes and hematopoiesis.
Combination Therapies Against the Apoptosis Sensitizing Target OPA1 for Overcoming Therapy Resistance in Acute Myeloid Leukemia
Innovative, efficacious, and novel treatment strategy for overcoming resistance to BH3 mimetics in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)
Personalized Ex Vivo Platform for Testing Patient Responsiveness to Therapeutics for Inflammatory Disorders
A novel and innovative organoid co-culture system for studying immune-mediated tissue damage and testing patient responses to therapies for inflammatory disorders.
iCADD: Next-generation Screening Platform for Identifying Small Molecular Glue Degraders
An efficient, high-throughput platform to rapidly identify protein degraders targeting undruggable proteins for therapeutic development.
Novel Screening Platform to Identify Confirmation-Specific SHP2 Inhibitors
A novel screening platform to discover inhibitors targeting signaling active form ("on") conformation to overcome drug resistance in RAS-driven cancers and genetic disorders.
Tumor-Targeting Nanoparticles for Precision Chemotherapy in Cancer
Precision drug delivery system to enhance on-target drug potency while minimizing off-target effects and toxicity.
Inhibitory Peptides That Selectively Antagonize Neuropilin 1 (NRP1) for Precise Pain Treatment
Differentiated and precise approach for selectively targeting pain receptors to treat different types of pain effectively and safely without use of opioids.
Innovative IGF-2 Receptor Agonists for Treating Neurodevelopmental Disorders and Neurodegenerative Diseases
Disease-modifying therapy with differentiated mechanisms of action to restore memory and motor function in neurodegenerative diseases and neurodevelopmental disorders.
Peptidomimetic Modulator of CaV2.2 N-type Calcium Channel for Treatment of Chronic Pain
Effective and non-addictive chronic pain therapeutics with minimal side effects.
Innovative Clasping Antibody Platform for Producing High-Performance Antibodies to Challenging Targets
An innovative platform for generating antibodies with high affinity, high specificity, and low lot-to-lot variability against challenging target antigens.
In Silico, Machine Learning-Based Platform to Identify Disease-Causing Senescent Cells
Accurate and reproducible method to identify senescent cells for diagnostic and therapeutic applications.
Prognostic Tool for Risk Stratifying Patients with Epilepsy to Improve Clinical Outcomes
Earlier and more accurate method to diagnose and treat Status Epilepticus (SE) and New-Onset Refractory Status Epilepticus (NORSE).
CX3CR-1GFP transgenic mice (B6.129P2(Cg)-Cx3cr1tm1Litt/J; Jax stock number: 005582)
The CX3CR-1GFP knock-in/knock-out mice express EGFP in monocytes, dendritic cells, NK cells, and brain microglia under control of the endogenous Cx3cr1 locus. These mice may be useful in studies of leukocyte migration and trafficking, as well as for transplantation studies.
Platform for Locally Assembling Antibody Drug Conjugates (ADCs) With Enhanced Specificity
Next-generation ADC platforms with high specificity and reduced systemic toxicity
Natural & Semi-Synthetic Prodrugs as Selective Antibiotics Against Colibactin-Producing E. coli for Colorectal Cancer Prevention
Precise and preventive therapeutic strategy for patients with a high risk of developing colorectal cancer.
Bright and Photostable Cyanine Dye Tags for Research Applications
Protein tags with high affinity and selectivity for off-the-shelf commercially-available fluorescent dyes that enhance their spectral properties.
Colonic Irrigation Solution
An efficacious, convenient, and easily tolerated method for improving polyp detection during routine colonoscopy procedures.
Cysteine Depletion as a Treatment for Obesity and Associated Metabolic Disorders
A rapid, safe, and tunable method of weight loss and metabolic regulation in the context of obesity and associated metabolic disorder treatment.
Repurposing Farnesyl Transferase Inhibitors for the Treatment of Cerebral Malaria
First-in-class treatment of cerebral malaria by preventing the pathological loss of the blood-brain barrier.
Apoptosis Inhibitor 5 (API5)-based Therapeutic for the Treatment of Inflammatory Bowel Diseases
A novel disease-modifying treatment of inflammatory bowel diseases that doesn't compromise the patient immune system.
Selective KRAS(G12D)-Binding Monobodies for the Treatment of Cancer
A selective, efficacious and versatile treatment for KRAS(G12D)-driven cancers
Selective NRAS-Binding Monobodies for the Treatment of Cancer
A selective and efficacious inhibitor of NRAS applicable to all NRAS-driven cancers.
Catalysts to Efficiently Convert Lignin Biomass to Valuable and Sustainable Chemicals
A highly efficient, selective, and sustainable method for converting lignin biomass into valuable, small molecule chemicals.
miRNA-Mediated Transgene Expression System for Improved Gene Therapies and Research Reagent Applications
A highly specific and tailorable transgene expression systems compatible with conventional gene therapy platforms
Multivalent Assembled Proteins (MAPs): Therapeutics for Cancer and Infectious Diseases
Tailorable multivalent therapeutic for targeting difficult protein-protein interaction (PPI) interfaces in the context of cancer and infectious diseases
Aryl-Diazonium Analogues as Potent DNA Cleavage Agents for Treating Cancer and Bacterial Infections
Potent, specific, modular, cost-effective, and synthetically-accessible agents for cytotoxic DNA cleavage.
Chip-based Prognostic Tool for Improved Leukemia Treatment Outcomes
Accurate, inexpensive, and rapid predictive tool to assess patient responsiveness to immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
Innovative therapies to overcome resistance to KRAS G12C inhibitors (G12Cis) in KRAS-mutant cancers.
Novel Probiotic Compositions for Improving Metabolism and Immunity
Innovative probiotic formulation to prevent and treat metabolic and immune disorders
Novel Class of Anthelmintic Compounds and Proprietary Screening Method for Anthelmintic Discovery
Novel anthelmintics with differentiated mechanisms of actions and therapeutic efficacy across multiple developmental stages
Therapeutic Hyaluronic Acid and Peptide Composition for Regenerative Repair of Cartilage Injury
Innovative disease-modifying method to treat knee cartilage injuries and prevent development of post-traumatic osteoarthritis (PTOA)
Injectable Therapeutic Hydrogel for the Treatment of Post-Traumatic Osteoarthritis
Injectable, minimally invasive, and effective disease-modifying therapeutic for post-traumatic osteoarthritis (PTOA) prevention and treatment
Biomarkers of Severe and Cerebral Malaria
Diagnostic and prognostic proteinaceous biomarker for severe and cerebral malaria
Salt-Inducible Kinase Activators to Treat Bone and Mineral Diseases
An innovative and efficacious oral treatment for bone and mineral diseases.
Small Molecule Inhibitors of SPNS2 for the Treatment of Chronic Inflammatory Diseases
Screening Method and Gene Therapy Approach for Treating Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)
An innovative and efficacious treatment targeting the genetic drivers of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
Apolipoprotein B Peptide Mimics for Atherosclerosis Treatment
Innovative, efficacious and complementary non lipoprotein-lowering treatments for atherosclerosis.
Efficient and High-Throughput Tool to Engineer Aligned 3D Collagen Matrices for Tissue Culture
Targeting Endocytosis in Nociceptors as a Non-Opioid Treatment Strategy for Chronic Pain
IL-17 Receptor Modulator Screen
Vectored ACE2 Receptor Decoy for Prevention and Treatment of Pan-Coronavirus Infections
Innovative, alternative, and complementary treatment option for pan-coronavirus infections
Nanobodies Targeting SARS-CoV-2 NSP9 for COVID Treatment
Saliva-Based Cytokine Score to Predict the Severity of Clinical Periodontal Inflammation
CD11c-DTR Transgenic Mice (B6.FVB-1700016L21RikTg [Itgax-DTR/EGFP] 57Lan/J; Jax stock number: 004509 )
The CD11c-DTR/GFP transgenic line 57 has the CD11c promoter (Itgax) directing expression of a diphtheria toxin receptor - enhanced green fluorescent protein (DTR/GFP) fusion protein to dendritic cell populations. (B6.FVB-1700016L21RikTg [Itgax-DTR/EGFP] 57Lan/J; Jax stock number: 004509 )
TET2 Conditional Knockout Transgenic Mice
Conditionally-inducible mouse model for studying hematopoietic stem cell self-renewal and myeloid transformation. (B6;129S-Tet2tm1.1Iaai/J; Jax stock number: 017573)
iScore: A Novel Method for Improved Risk Stratification of AML Patients
Robust and innovative method for accurate classification of AML patients to enable personalized treatment approaches
Targeting the SARS-CoV-2 Viral-Immune Interaction for COVID-19 Therapy
New and innovative therapeutic approaches for blocking SARS-CoV-2 engagement with immune cells
Viral Vector Expression of Gabrb1b for the Treatment of Perceptual Deficits
Innovative and targeted approaches to treat perceptual deficits associated with reduced GABA receptor-mediated inhibitory postsynaptic potentials.
Steroid Modulators of Treg Lymphocytes and Pro-Inflammatory T Helper Cells For Autoimmune Disease
Innovative methods to modulate host T regulatory (Treg) and Th17 cells in autoimmune disease treatment.
Targeting a Novel Metabolic Network for Pancreatic Ductal Adenocarcinoma (PDAC) Treatment
New and innovative therapeutic approaches for efficient PDAC treatment
Paper-Based, Multiplexed Lamp Diagnostic for Pathogen Detection
Easy-to-use, inexpensive, accurate, and customizable pathogen detection devices.
Engineered Progranulin: A Promising Therapeutic Approach for Autoimmune Diseases
New efficacious TNFα inhibitors for the treatment of Rheumatoid arthritis and other autoimmune diseases.
PHOTACS: Photo-Activatable PROTACS
Spatial and temporal control over protein target degradation in diseased tissue
Multivalent Steroid Conjugates for Treatment of Castration-Resistant Prostate Cancer (CRPC)
A new generation of therapeutics for treating patients with enzalutamide-resistant CRPC.
Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
Innovative and effective therapies for treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH)
FGF23 Ligand Trap: New Biologic for Treating Kidney Diseases
Innovative and efficacious treatments for chronic kidney disease and phosphate-wasting diseases.
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
New and efficacious versions of fibroblast growth factor 21 (FGF21) for metabolic liver diseases
Adhesive Bandage for Rapid Pathogen Immune Response Detection
Innovative, portable, and customizable diagnostic devices for detecting an individual’s anti-pathogen immune response.
Angiotensin-Converting Enzyme 2 (ACE2) Immunoadhesin Microbody
Improved therapeutic approaches for blocking SARS-CoV-2 entry into host cells
Nano Zeolite-Y: A Novel and Cost-Effective Antibacterial Composition
A novel and cost-effective inorganic antibacterial composition.
ASOs Targeting CHROMR for the Treatment of Inflammatory Diseases
Innovative, efficacious, and patient-specific treatment for chronic inflammatory diseases mediated by hyperactive type-I interferon responses.
PKP2cKO Transgenic Mouse Model
Conditionally-inducible mouse model for arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited type of heart disease that can cause sudden death.
Anti-CD99 Antibodies Cytotoxic to Leukemia
New anti-CD99 antibodies for the treatment of rare hematological malignancies
Oral Insulin Delivery Nanoparticles for Diabetes Treatment
An improved method for insulin delivery that is more convenient and non-invasive.
Photoactivatable Lipid Nanoparticles for Drug Delivery
Novel photoactivatable lipid nanoparticles for drug delivery that allow for light-triggered drug release at the disease site
TET2 Modulators for the Treatment of Cancer and Inflammatory Diseases
A series of small molecule modulators (agonists and antagonists) of TET2 for potential use as therapeutics for rare hematological diseases.
Succinate Receptor 1 (SUCNR1) Antagonists to Treat Neuroinflammation
A promising therapeutic target for the prevention and/or treatment of neurodegenerative diseases.
Avobenzone-Dendrimer Conjugates
The use of a dendrimer scaffold to stabilize avobenzone in sunscreens and improve photochemical properties.
NSP14/10 Complex Inhibitors for the Treatment of SARS-CoV-2 and Pan-Coronavirus Infections
Innovative and efficacious therapeutic to treat current and future pan-coronavirus infections